Viruses exploit the function of epidermal growth factor receptor

Reviews in Medical Virology

Volumn 24, Issue 4, 2014, Pages 274-286

  Zheng, Kai ^a   Kitazato, Kaio ^b   Wang, Yifei ^a  

^a JINAN UNIVERSITY   (China)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; F ACTIN;

ANGIOGENESIS; ARTICLE; CELL SURVIVAL; ENDOCYTOSIS; LIGAND BINDING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; VIRUS; VIRUS ENTRY; VIRUS REPLICATION; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; VIRAL PHENOMENA AND FUNCTIONS;

HOST-PATHOGEN INTERACTIONS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VIRUS PHYSIOLOGICAL PHENOMENA;

EID: 84903820005     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1796     Document Type: Article

References (100)

1. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Seminar in Oncology 2006; 33: 369-385.
2. Dunn GP, Rinne ML, Wykosky J, et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes and Development 2012; 26: 756-784.
3. Wykosky J, Fenton T, Furnari F, Cavenee WK. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer 2011; 30: 5-12.
4. Stewart AR, Tollefson AE, Krajcsi P, Yei SP, Wold WS. The adenovirus E3 10·4K and 14·5K proteins, which function to prevent cytolysis by tumor necrosis factor and to down-regulate the epidermal growth factor receptor, are localized in the plasma membrane. Journal of Virology 1995; 69: 172-181.
5. Prudenziati M, Sirito M, van Dam H, Ravazzolo R. Adenovirus E1A down-regulates the EGF receptor via repression of its promoter. International Journal of Cancer 2000; 88: 943-948.
6. Hoffman P, Carlin C. Adenovirus E3 protein causes constitutively internalized epidermal growth factor receptors to accumulate in aprelysosomal compartment, resulting in enhanced degradation. Molecular and Cellular Biology 1994; 14: 3695-3706.
7. Bowick GC, Fennewald SM, Scott EP, et al. Identification of differentially activated cell signaling networks associated with pichinde virus pathogenesis by using systems kinomics. Journal of Virology 2007; 81: 1923-1933.
8. Sánchez EG, Quintas A, Pérez-Núñez D, et al. African swine fever virus uses macrophinocytosis to enter host cells. PLOS Pathogens 2011; 8: e1002754.
9. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nature Medicine 2011; 17: 589-595.
10. Brenndörfer ED, Karthe J, Frelin L, et al. Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 2009; 49: 1810-1820.
11. Diao J, Pantua H, Ngu H, et al. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. Journal of Virology 2012; 86: 10935-10949.
12. Zona L, Lupberger J, Sidahmed-Adrar N, et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host & Microbe 2013; 13: 302-313.
13. Farquhar MJ, Harris HJ, McKeating JA. Hepatitis C virus entry and the tetraspanin CD81. Biochemical Society Transactions 2011; 39: 532-536.
14. Lupberger J, Duong EHT, Fofana I, et al. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology 2013; 58: 1225-1235.
15. Mankouri J, Griffin S, Harris M. The Hepatitis C virus non-structural protein NS5A alters the trafficking profile of the epidermal growth factor receptor. Traffic 2008; 9: 1497-1509.
16. Menzo S, Clementi M, Alfani E, et al. Transactivation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. Virology 1993; 196: 878-882.
17. Chen YJ, Chien PH, Chen WS, et al. Hepatitis B virus-encoded X protein downregulates EGFR expression via inducing microRNA-7 in hepatocellular carcinoma cells. Evidence-based Complementary and Alternative Medicine 2013; 2013: 682380.
18. Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 2003; 424: 456-461.
19. Wang X, Huang DY, Huong SM, Huang ES. Integrin αvβ3 is a coreceptor for human cytomegalovirus. Nature Medicine 2005; 11: 515-521.
20. Compton T, Nepomuceno RR, Nowlin DM. Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface. Virology 1992; 191: 387-395.
21. Bentz GL, Yurochko AD. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 and beta3 integrins. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 5531-5536.
22. LaMarca HL, Nelson AB, Scandurro AB, Whitley GS, Morris CA. Human cytomegalovirus-induced inhibition of cytotrophoblast invasion in a first trimester extravillous cytotrophoblast cell line. Placenta 2006; 27: 137-147.
23. Maidji E, Genbacev O, Chang HT, Pereira L. Developmental regulation of human cytomegalovirus receptors in cytotrophoblasts correlates with distinct replication sites in the placenta. Journal of Virology 2007; 81: 4701-4712.
24. Chan G, Nogalski MT, Yurochko AD. Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 22369-22374.
25. Fairley JA, Baillie J, Bain M, Sinclair JH. Human cytomegalovirus infection inhibits epidermal growth factor (EGF) signaling by targeting EGF receptors. Journal of General Virology 2002; 83: 2803-2810.
26. Jafferji I, Bain M, King C, Sinclair, JH. Inhibition of epidermal growth factor receptor (EGFR) expression by human cytomegalovirus correlates with an increase in the expression and binding of Wilms' Tumour 1 protein to the EGFR promoter. Journal of General Virology 2009; 90: 1569-1574.
27. Schleiss M, Eickhoff J, Auerochs S, et al. Protein kinase inhibitors of the quinazoline class exert anti-cytomegalovirus activity in vitro and in vivo. Antiviral Research 2008; 79: 49-61.
28. Zheng K, Xiang Y, Wang X, et al. Epidermal growth factor receptor (EGFR)-PI3K signaling controls cofilin activity to facilitate Herpes simplex virus type 1 entry into neuronal cells. mBio 2014; 5: e00958-13.
29. Liang Y, Kurakin A, Roizman B. Herpes simplex virus 1infected cell protein 0 forms a complex with CIN85 and Cbl and mediates the degradation of EGF receptor from cell surfaces. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 5838-5843.
30. Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phsophatidylinositol 3-kinase/akt pathway to promote cell survival and induce actin filament remodeling. Journal of Biological Chemistry 2003; 278: 3694-3704.
31. Kung CP, Meckes DG Jr, Raab-Traub N. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCδ. Journal of Virology 2011; 85: 4399-4408.
32. Xu Y, Shi Y, Yuan Q, et al. Epstein-Barr Virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. Journal of Experimental & Clinical Cancer Research 2013; 32: 90.
33. Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. Journal of Virology 1995; 69: 4390-4398.
34. Thornburg NJ, Raab-Traub N. Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal activating region 1 is mediated by NF-κB p50 homoimer/bcl-3 complexes. Journal of Virology 2007; 81: 12954-12961.
35. Karlas A, Machuy N, Shin Y, et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010; 463: 818-822.
36. Eierhoff T, Hrincius ER, Rescher U, Ludwig S, Ehrhardt C. The epidermal growth factor receptor (EGFR) promotes uptake of influenza A virus (IAV) into host cells. PLOS Pathogens 2010; 6: e1001099.
37. Zhu L, Ly H, Liang Y. PLC-γ1 signaling plays a subtype-specific role in post binding cell entry of influenza A virus. Journal of Virology 2014; 88: 417-424.
38. Barik S. Respiratory syncytial virus mechanisms to interfere with type 1 interferons. Current Topics in Microbiology and Immunology 2013; 372: 173-191.
39. Barbier D, Garcia-Verdugo G, Pothlichet J, et al. Influenza A induces the major secreted airway mucin MUC5AC in a protease-EGFR-extracellular regulated kinase-Sp1-dependent pathway. American Journal of Respiratory Cell and Molecular Biology 2012; 47: 149-157.
40. Surviadze Z, Sterk RT, DeHaro SA, Ozbun MA. Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy. Journal of Virology 2013; 87: 2508-2517.
41. Schelhaas M, Shah B, Holzer M, et al. Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft -independent endocytosis. PLOS Pathogens 2012; 8: e1002657.
42. Straight SW, Herman B, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. Journal of Virology 1995; 69: 3185-3192.
43. Krzyzaniak MA, Zumstein MT, Gerez JA, Picotti P, Helenius A. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLOS Pathogens 2013; 9: e1003309.
44. Villenave R, Shields MD, Power UF. Respiratory syncytial virus interaction with human airway epithelium. Trends in Microbiology 2013; 21: 238-244.
45. Monick MM, Cameron, K, Staber J, et al. Activation of the epidermal growth factor receptor by respiratory syncytial virus results in increased inflammation and delayed apoptosis. Journal of Biological Chemistry 2005; 280: 2147-2158.
46. Tyner JW, Kim EY, Ide K, et al. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. Journal of Clinical Investigation 2006; 116: 309-321.
47. Malur AG, Chattopadhyay S, Maitra RK, Banerjee AK. Inhibition of STAT 1 phosphorylation by human parainfluenza virus type 3 C protein. Journal of Virology 2005; 79: 7877-7882.
48. Caignard G, Komarova AV, Bouraï M, et al. Differential regulation of type 1 interferon and epidermal growth factor pathways by a human respirovirus virulence factor. PLOS Pathogens 2009; 5: e1000587.
49. Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Silvio Gutkind J, Chiorini JA. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nature Medicine 2010; 16: 662-664.
50. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for huan gene therapy. Molecular Therapy 2009; 14: 316-327.
51. Zhong L, Zhao W, Wu J, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Molecular Therapy 2007; 15: 1323-1330.
52. Tung WH, Hsieh HL, Lee IT, Yang CM. Enterovirus 71 induces intergrin β1/EGR-Rac1-dependent oxidative stress in SK-N-SH cells: role of HO-1/CO in viral replication. Journal of Cellular Physiology 2011; 226: 3316-3329.
53. Ueki IF, Min-Oo G, Kalinowski A, et al. Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium. Journal of Experimental Medicine 2013; 210: 1929-1936.
54. Zhu L, Lee P, Lee W, Zhao Y, Yu D, Chen Y. Rhinovirus-induced major airway mucin production involves a novel TLR3-EGFR-dependent pathway. American Journal of Respiratory Cell and Molecular Biology 2008; 40: 610-619.
55. Hewson CA, Haas JJ, Bartlett NW, et al. Rhinovirus induces MUC5AC in a human infection model and in vitro via NF-κB and EGFR pathways. European Respiratory Journal 2010; 36: 1425-1435.
56. Liu K, Gualano RC, Hibbs ML, Anderson GP, Bozinovski S. Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory response to rhinovirus infection. Journal of Biological Chemistry 2008; 283: 9977-9985.
57. Yang H, Kim SK, Kim M, et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. Journal of Clinical Investigation 2005; 115: 379-387.
58. Langhammer S, Koban R, Yue C, Ellerbrok H. Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (IressaTM). Antiviral Research 2011; 89: 64-70.
59. Mercer J, Knébel S, Schmidt FI, Crouse J, Burkard C, Helenius A. Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 9346-9351.
60. Opgenorth A, Nation N, Graham K, McFadden G. Transforming growth factor-α, Shope fibroma virus factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits. Virology 1993; 192: 701-709.
61. Tzahar E, Moyer JD, Waterman H, et al. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO Journal 1998; 17: 5948-5963.
62. Butler NJ, Thorne JE. Current status of HIV infection and ocular disease. Current Opinion in Ophthalmology 2012; 23: 517-522.
63. Wojcechowskyj JA, Didigu CA, Lee JY, et al. Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry. Cell Host & Microbe 2013; 13: 613-623.
64. Valiathan RR, Resh MD. Expression of human immunodeficiency virus type 1 gag modulates ligand-induced downregulation of EGF receptor. Journal of Virology 2004; 78: 12386-12394.
65. Adelsman MA, Huntley BK, Maihle NJ. Ligand independent dimerization of oncogenic v-erbB products involves covalent interactions. Journal of Virology 1996; 70: 2533-2544.
66. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. Journal of Virology 1996; 70: 612-616.
67. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature Reviews. Clinical Oncology 2010; 7: 493-507.
68. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials 2013; 34: 8690-8707.
69. Diehl N, Schaal H. Make yourself at home: viral hijacking of the PI3k/Akt signaling pathway. Viruses 2013; 5: 3192-3212.
70. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathways as drug target in human cancer. American Society of Clinical Oncology 2010; 28: 1075-1083.
71. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Developmental Cell 2008; 15: 209-219.
72. McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nature Reviews Molecular Cell Biology 2011; 12: 517-533.
73. Sousa LP, Lax I, Shen H, Ferguson SM, De Camilli P, Schlessinger J. Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: 4419-4424.
74. Mooren OL, Galletta BJ, Cooper JA. Roles for actin assembly in endocytosis. Annual Review of Biochemistry 2012; 81: 661-686.
75. Endres NF, Das R, Smith AW, et al. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 2013; 152: 543-556.
76. Grossier JP, Xouri G, Goud B, Schauer K. Cell adhesion defines the topology of endocytosis and signaling. EMBO Journal 2014; 33: 35-45.
77. Vehlow A, Soong D, Vizcay-Barrena G, et al. Endophilin, Lamellipodin, and Mena cooperate to regulate F-actin-dependent EGF-receptor endocytosis. EMBO Journal 2013; 63: 2722-2734.
78. Mercer J, Schelhaas M, Helenius A. Virus entry by endocytosis. Annual Review of Biochemistry 2010; 79: 803-833.
79. Taylor MP, Koyuncu OO, Enquist LW. Subversion of the actin cytoskeleton during viral infection. Nature Reviews Microbiology 2011; 9: 427-439.
80. Marsh M, Helenius A. Virus entry: Open sesame. Cell 2006; 124: 729-740.
81. Grove J, Marsh M. The cell biology of receptor-mediated virus entry. Journal of Cell Biology 2009; 195: 1071-1082.
82. Isaacson MK, Feire AL, Compton T. Epidermal growth factor receptor is not required for human cytomegalovirus entry or signaling. Journal of Virology 2007; 81: 6241-6247.
83. Cobbs CS, Soroceanu L, Denham S, et al. Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness. Journal of Neuro-Oncology 2007; 85: 271-280.
84. Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008; 455: 391-395.
85. Grünwald GK, Vetter A, Klutz K, et al. EGFR-targeted adenovirus dendrimer coating for improved systemic delivery of the thernostic NIS gene. Molecular Therapy Nucleic Acids 2013; 2: e131.
86. Plemper RK. Cell entry of enveloped viruses. Current Opinion Virology 2011; 1: 92-100.
87. Mercer J, Helenius A. Virus entry by macropinocytosis. Nature Cell Biology 2009; 11: 510-520.
88. MacLeod IJ, Minson T. Binding of herpes simplex virus type-1 virions leads to the induction of intracellular signaling in the absence of virus entry. PloS One 2010; 5: e9560.
89. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signaling, antiviral responses and virus countermeasures. Journal of General Virology 2008; 898: 1-47.
90. Miller WE, Raab-Traub N. The EGFR as a target for viral oncoproteins. Trends in Microbiology 1999; 7: 453-458.
91. Levkowitz G, Waterman H, Zamir E, et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes and Development 1998; 12: 3663-3674.
92. Yaro A. Epstein-Barr infection: current treatment options. Annals of Tropical Medicine and Public Health 2013; 6: 10-13.
93. Vela EM, Bowick GC, Herzog NK, Aronson JF. Exploring kinase inhibitors as therapies for human arenavirus infections. Future Virology 2008; 3: 243-251.
94. Paraskevakou G, Allen C, Nakamura T, et al. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRvIII expressing gliomas. Molecular Therapy 2007; 15: 677-686.
95. de Bruin K, Ruthardt N, von Gersdorff K, et al. Cellular dynamics of EGF receptor-targeted synthetic viruses. Molecular Therapy 2007; 15: 1297-1305.
96. Muniz-Feliciano L, van Grol J, Portillo JA, et al. Toxoplasma gondii-induced activation of EGFR prevents autophagy protein-mediated killing of the parasite. PLOS Pathogens 2013; 9: e1003809.
97. Pachathundikandi SK, Tegtmeyer N, Backert S. Signal transduction of Helicobacter pylori during interaction with host cell protein receptors of epithelial and immune cells. Gut Microbes 2013; 4(6) 454-474.
98. Zhu W, Phan QT, Boontheung P, Solis NV, Loo JA, Filler SG. EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: 14194-14199.
99. Ramel D, Lagarrigue F, Pons V, et al. Shigella flexneri infection generates the lipid PI5P to alter endocytosis and prevent termination of EGFR signaling. Science Signaling 2011; 4: ra61.
100. Kim J, Kim N, Park JH, et al. The effect of Helicobacter pylori on epidermal growth factor receptor-induced signal transduction and the preventive effect of Celecoxib in gastric cancer cells. Gut Liver 2013; 7: 552-559.